Cartoon depicting dexamethasone and dasatinib metabolism and efflux transport in intestine and liver. by Kavya Annu (11587215)

Gene expression (qPCR) data from livers of C57BL/6 mice before and after DEX treatment. by Kavya Annu (11587215)

Raw data from survival study in VD₃ sufficient vs. deficient male mice from BCR-ABL ALL when treated with dexamethasone. by Kavya Annu (11587215)

Gene expression (qPCR) data from VD3 sufficient and deficient hCYP3A4 12-week-old mice liver and kidney. by Kavya Annu (11587215)

Gene expression (qPCR) data from VD3 sufficient and deficient C57BL/6 mice duodenum. by Kavya Annu (11587215)

Gene expression (qPCR) data from duodenums of C57BL/6 mice before and after DEX treatment. by Kavya Annu (11587215)

Gene expression (qPCR) data from VD3 sufficient and deficient hCYP3A4 12-week-old mice duodenum. by Kavya Annu (11587215)

Kaplan-Meier curves for the effect of VD₃ sufficiency vs. deficiency on survival of mice from BCR-ABL Arf-/- leukemia. by Kavya Annu (11587215)

Cyp and transporter gene expression in liver and kidney of 12-week-old hCYP3A4 mice. by Kavya Annu (11587215)

Differences in plasma and gut dexamethasone concentrations following the oral discontinuous DEX regimen leads to tissue specific activation of GCR and PXR. by Kavya Annu (11587215)

Cartoon depicting hypothesis that dexamethasone-activated PXR can induce Cyp3a in VD₃ deficient mice, but not in VD₃ sufficient mice where 1,25(OH)<sub>2</sub... by Kavya Annu (11587215)

Dexamethasone plasma pharmacokinetics in male and female VD₃ sufficient and deficient mice, aged 14 weeks, after a single oral gavage of 2 mg/kg dexamethasone phosphate. by Kavya Annu (11587215)

Dasatinib plasma pharmacokinetics in male and female VD₃ sufficient and deficient mice after a single oral gavage of 10 mg/kg dasatinib. by Kavya Annu (11587215)

Lumen diameter (77.9±5.6 vs 120.6±5.5 µm at 75 mmHg, <i>p</i><0.001), external diameter (110.4±6.4 vs 153.1±5.2 µm at 75 mmHg, <i>p</i><0.001) and media cross-sectional area (4860.4±464.7 vs 6972.4±272.1 µm² at 75 mmHg, <i>p</i><0.001) were increased in 16 wk-old db/db MRAs while wall:lumen ratio (21.3±1.2 vs 13.7±0.8 at 75 mmHg, <i>p</i><0.01) was decreased when compared to Db/db mice under physiological pressures of 50, 75 and 100 mmHg: a.... by Flavia M. Souza-Smith (346803)

Data_Sheet_1_METTL3/m6A/miRNA-873-5p Attenuated Oxidative Stress and Apoptosis in Colistin-Induced Kidney Injury by Modulating Keap1/Nrf2 Pathway.docx by Jian Wang (5901)

“…Levels of m⁶A are decreased after colistin treatment in mRTECs. …”

Data from paper "<b>Selectively vulnerable deep cortical layer 5/6 fast-spiking interneurons in Alzheimer’s Disease models </b><b><i>in vivo</i></b>", Papanikolaou et al., Neuron 2... by Amalia Papanikolaou (20974103)

“…These dysfunctions occurred alongside a deep layer-specific reduction in neuronal pentraxin 2 (NPTX2) within excitatory neurons, decreased GluA4 in PV-FSIs, and fewer excitatory synapses onto PV-FSIs. …”

Structural Basis for Sequence Specific DNA Binding and Protein Dimerization of HOXA13 by Yonghong Zhang (20918)

“…I366 makes similar methyl contacts with T3* and T4*. Mutants (I366A, N370A and V373G) all have decreased DNA binding and transcriptional activity. …”

<i>Cotton Leaf Curl Multan virus</i> C4 protein suppresses both transcriptional and post-transcriptional gene silencing by interacting with SAM synthetase by Asigul Ismayil (5698946)

“…Plants infected with CLCuMuV carrying C4^R13A show decreased levels of symptoms and viral DNA accumulation associated with enhanced viral DNA methylation. …”

Supplementary Material for: Hyperfunctioning Papillary Thyroid Carcinoma with a <b><i>BRAF</i></b> Mutation: The First Case Report and a Literature Review by Shinkai S. (10260734)

“…<b><i>Introduction:</i></b> Hyperfunctioning papillary thyroid carcinoma (PTC) is rare and consequently, little information on its molecular etiology is available. Although <i>BRAF</i> V600E (<i>BRAF</i> c.1799T>A, p.V600E) is a prominent oncogene in PTC, its mutation has not yet been reported in hyperfunctioning PTC. …”

Image_5_COVID-19 Pandemic and Trends in Clinical Trials: A Multi-Region and Global Perspective.TIF by Satoshi Nishiwaki (560641)

“…Similarly, the mean percentage change of reported results for each month in 2019 and 2020 was −5.1%, with the maximum of −27.4% observed in July 2020. …”